US 11,832,920 B2
Devices, systems, and methods for pulmonary arterial hypertension (PAH) assessment and treatment
Jason White, Smyrna, GA (US); Ralph Jordan, Atlanta, GA (US); John Erik Moore, Roswell, GA (US); and Jay Yadav, Sandy Springs, GA (US)
Assigned to ST. JUDE MEDICAL LUXEMBOURG HOLDINGS II S.A.R.L. (“SJM LUX II”), Luxembourg (LU)
Filed by ST. JUDE MEDICAL LUXEMBOURG HOLDINGS II S.A.R.L. (“SJM LUX II”), Luxembourg (LU)
Filed on Jun. 5, 2020, as Appl. No. 16/893,542.
Application 16/893,542 is a continuation of application No. 14/086,478, filed on Nov. 21, 2013, granted, now 10,709,341.
Claims priority of provisional application 61/799,536, filed on Mar. 15, 2013.
Claims priority of provisional application 61/728,913, filed on Nov. 21, 2012.
Prior Publication US 2020/0297218 A1, Sep. 24, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 5/0215 (2006.01); G16H 50/20 (2018.01); A61B 5/029 (2006.01); A61B 5/02 (2006.01); A61B 5/00 (2006.01); G16H 20/10 (2018.01)
CPC A61B 5/0215 (2013.01) [A61B 5/002 (2013.01); A61B 5/029 (2013.01); A61B 5/02028 (2013.01); A61B 5/686 (2013.01); A61B 5/7275 (2013.01); A61B 5/7282 (2013.01); G16H 20/10 (2018.01); G16H 50/20 (2018.01); A61B 5/02 (2013.01); A61B 2560/0219 (2013.01); A61B 2560/0228 (2013.01); A61B 2562/0247 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of evaluating progress of pulmonary arterial hypertension (PAH) in a subject, or an outcome in the subject having PAH, comprising:
obtaining pulmonary artery pressure (PAP) data over a cardiac cycle from a wireless pressure sensor implanted in a pulmonary artery of the subject, the wireless pressure sensor wirelessly communicating with a base unit, the base unit communicating with a second computer;
utilizing a processor of at least one of the base unit or second computer for:
determining first and second PAP values experienced within the pulmonary artery based on the PAP data;
estimating first and second cardiac outputs (COs) based on the first and second PAP values experienced within the pulmonary artery over the cardiac cycle;
comparing the first and second PAP values and comparing the first and second COs;
monitoring a PAH progression or outcome in the subject based on the comparing of first and second PAPs and first and second COs; and
changing at least one of a pharmaceutical agent, dosage or dosing regimen based on the PAH progression or outcome in the subject.